Shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) have earned a consensus recommendation of “Buy” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $32.69.
A number of analysts recently issued reports on GLMD shares. ValuEngine upgraded shares of Galmed Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 6th. Cantor Fitzgerald set a $59.00 price objective on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 5th. Zacks Investment Research downgraded shares of Galmed Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 16th. HC Wainwright decreased their price objective on shares of Galmed Pharmaceuticals to $28.00 and set a “buy” rating for the company in a report on Monday, January 14th. Finally, B. Riley started coverage on shares of Galmed Pharmaceuticals in a report on Tuesday, December 11th. They set a “buy” rating and a $28.00 price objective for the company.
Shares of GLMD stock opened at $7.34 on Friday. Galmed Pharmaceuticals has a one year low of $3.61 and a one year high of $27.06. The stock has a market capitalization of $116.76 million, a PE ratio of -7.49 and a beta of 2.70.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Recommended Story: What is a stock split?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.